Gp Limited Partnership Ahls III files SEC Form 4 disclosures for Aegerion Pharmaceuticals, Inc.. They have made 7 open-market trades across 1 company since 2010, most recently 2012-03-09.
CIK 0001227915
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $2.5M since 2010, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AEGR | 2,430,765 | $4.8M |
Shares reported on the most recent Form 4, priced at the 2012-03-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AEGR | SELL | 2012-03-09 | 2012-03-14 | $15.87 | $1.6M | -26.4% | -3.7% | -3.7% |
| AEGR | SELL | 2012-01-27 | 2012-01-31 | $17.15 | $1.3M | -26.4% | -3.7% | -3.7% |
| AEGR | SELL | 2011-12-08 | 2011-12-09 | $16.89 | $338K | -26.4% | -3.7% | -3.7% |
| AEGR | SELL | 2011-12-06 | 2011-12-08 | $16.96 | $93K | -26.4% | -3.7% | -3.7% |
| AEGR | SELL | 2011-07-29 | 2011-07-29 | $14.61 | $74K | -26.4% | -3.7% | -3.7% |
| AEGR | SELL | 2011-06-29 | 2011-06-29 | $14.61 | $1.8M | -26.4% | -3.7% | -3.7% |
| AEGR | BUY | 2010-10-27 | 2010-10-27 | $9.50 | $2.5M | -26.4% | -3.7% | -3.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.